Optiscan details strategic shift to digital pathology, precision surgery solutions

Optiscan Imaging Limited presented an investor update on December 4, 2025, outlining its transition from OEM to a digital solutions provider in digital pathology and precision surgery. The company reported revenue of $0.95m and an EBITDA of ($5.84m) for FY2025. As of September 30, 2025, total assets stood at $10.55m, with total liabilities at $2.84m. Cash reserves were $19.99m, following $17.75m in capital raised through a fully underwritten pro-rata renounceable entitlement offer in September 2025.

Key milestones for 2025 included a $1.775 R&D Tax Refund in January, the initiation of a GI Study in Germany with the first prototype in February, and the reveal of the InForm Imaging Device for Pathology in February. Optiscan also announced new CFO and executive appointments in March and advanced its Robotic Surgery Collaboration with Mayo Clinic in May. The company completed its cloud-based Telepathology Software MVP in May and introduced the InSpecta Device for Veterinary Medicine in June.

Further strategic advancements in 2025 included an agreement with Long Grove Pharmaceuticals and the initiation of a Breast Cancer Study at Royal Melbourne Hospital in June. Partnerships with Australian Clinical Labs and a keynote address at the Mayo Clinic Surgical Summit in November underscore its commitment to advancing digital pathology. The year concluded with the approval of a Head & Neck Cancer Imaging Study in December, utilizing its InVue® precision surgery and InForm™ digital pathology imaging devices.